IL17A and plasma cell myeloma: Thus, it may be speculated that although increased Tregs in myeloma may outweigh the number of myeloma permissive Th17 cells, the detrimental effect on Th17 cells may be compensated by reduced ability of Treg to suppress IL-17 production due to in increased proportion of CD39- Treg.